Time of administration of rabies immunoglobulins and adequacy of antibody response upon post-exposure prophylaxis: a descriptive retrospective study in Belgium

被引:8
|
作者
Soentjens, Patrick [1 ,2 ]
Croughs, Mieke [2 ]
Burm, Christoph [2 ]
Declerq, Steven [2 ]
Clerinx, Jan [2 ]
Maniewski, Ula [2 ]
Van den Broucke, Steven [2 ]
Theunissen, Caroline [2 ]
Huits, Ralph [2 ]
Brosius, Isabel [2 ]
Florence, Eric [2 ]
Kenyon, Chris [2 ]
Van Griensven, Johan [2 ]
Van Ierssel, Sabrina [3 ]
Lynen, Lut [2 ]
Balliauw, Katleen [4 ]
Van Gucht, Steven [3 ]
Van Esbroeck, Marjan [2 ]
Vlieghe, Erika [2 ,3 ]
Bottieau, Emmanuel [2 ]
Van Herrewege, Yven [2 ,5 ]
机构
[1] Queen Astrid Mil Hosp, Ctr Infect Dis, Brussels, Belgium
[2] Inst Trop Med, Dept Clin Sci, Antwerp, Belgium
[3] Univ Hosp Antwerp, Dept Infect Dis & Trop Dis, Antwerp, Belgium
[4] Univ Hosp Antwerp, Hosp Pharm, Antwerp, Belgium
[5] Sciensano, Natl Reference Ctr Rabies, Brussels, Belgium
关键词
Rabies; pre-exposure prophylaxis; post-exposure prophylaxis; VACCINATION;
D O I
10.1080/17843286.2019.1662993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Data on rabies post-exposure prophylaxis (PEP) and the use of human rabies immunoglobulins (HRIG) in Belgium are scarce. The main objective of this study was to evaluate the timely administration of HRIG after rabies exposure. The secondary objective was to evaluate the adequate antibody response following PEP. Methods: We reviewed all medical records from July 2017 to June 2018 of patients seeking care at, or referred to, the Institute of Tropical Medicine and the University Hospital, Antwerp for the administration of human rabies immunoglobulins following potential rabies exposure abroad or in Belgium. A timely response was defined as starting HRIG with a delay of <= 48 h and rabies vaccination in the first 7 days after exposure. Adequate antibody response was defined as a titer of >5.0 IU/mL in case of bat-related exposure and >3.0 IU/mL in case of exposure to other animals. Titers were measured 10 days after the last PEP vaccine dose, using the rapid fluorescent focus inhibition test (RFFIT). Results: Of the 92 cases treated with HRIG, 75 were evaluated. The majority of injuries were acquired in Asia (n = 26,34%) and in Western Europe (n = 18, 24%), of which 17 in Belgium. The five most frequently recorded countries overseas were Indonesia (n = 13), Thailand (n = 7), Morocco (n = 4), Peru (n = 3) and Costa Rica (n = 3). Administration of immunoglobulins was related to injuries by dogs (36%), monkeys (25%) or bats (22%). A timely response was observed in 16 (21,33%) and in 55 (73,33%) of subjects receiving HRIG (<= 48 h) or rabies vaccine (<7days) respectively. The mean time between exposure and the first administered dose of rabies vaccine and HRIG was 7.7 and 8.7 days, respectively. The mean delay for HRIG administration was 9.6 days and 6 days for abroad and inland risks, respectively. In 15 of 16 (94%) bat-related cases the antibody titer after full PEP was >5.0 IU/ml. In 38 of 47 (81%) cases related to other animals the RFFIT titer was >3.0 IU/ml. All low-responders received additional rabies injections. Conclusion: This study showed a substantial time delay between the animal-related risk and the administration of HRIG, in particular when the injury occurred abroad. More targeted communication about the risks of rabies and preventable measures may reduce this delay. Furthermore, the antibody response was inadequate in some cases following full PEP administration according to the Belgian recommendation.
引用
收藏
页码:91 / 97
页数:7
相关论文
共 50 条
  • [21] Acute bilateral vestibulocochlear neuritis following cultured cell vaccine administration for rabies post-exposure prophylaxis
    Mesquita, Emersom Cicilini
    Rouanet, Carolina
    Lucas, Gilberto Luciano
    de Lemos, Alberto dos Santos
    Lima, Marco Antonio
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 359 (1-2) : 84 - 85
  • [22] IMMUNE RESPONSE AND COST ANALYSIS OF INTRADERMAL RABIES VACCINATION FOR POST-EXPOSURE PROPHYLAXIS REGIMEN IN HUMAN
    Budayanti, N. S.
    Susilawathi, N. M.
    Darwinata, A. E.
    Dwija, I. B. P.
    Fatmawati, N. D.
    Wirasandhi, K.
    Subrata, K.
    Susilarini, N. K.
    Wignall, F. S.
    Sudewi, A. A. R.
    Mahardika, G. N. K.
    BALI MEDICAL JOURNAL, 2014, 3 (01) : 18 - 24
  • [23] Response to purified chick embryo cell rabies vaccine administered intradermally for post-exposure prophylaxis
    Madhusudana, SN
    Anand, NP
    NATIONAL MEDICAL JOURNAL OF INDIA, 1997, 10 (03): : 115 - 116
  • [24] Immune response to rabies post-exposure prophylaxis in patients with non-HIV secondary immunodeficiencies
    Parize, Perrine
    Poujol, Philippe
    Le Houssine, Pascale Morineau
    Goesch, Julia
    Lucet, Cora
    Basuyau, Laura
    Cailhol, Johann
    Dacheux, Laurent
    Bourhy, Herve
    Consigny, Paul-Henri
    VACCINE, 2020, 38 (33) : 5091 - 5094
  • [25] STEWARDLY USE OF RABIES POST-EXPOSURE PROPHYLAXIS IN A TIME OF SHORTAGE WITH TRIAGE BY A REGIONAL POISON CENTER
    Gorodetsky, Rachel
    Morgan, Brent
    Hon, Stephanie
    Geller, Robert
    CLINICAL TOXICOLOGY, 2011, 49 (06) : 600 - 600
  • [26] Post-exposure rabies prophylaxis in humans exposed to animals in Lublin province (Eastern Poland) in 2012-2015-A retrospective study
    Krzowska-Firych, Joanna
    Tomasiewicz, Krzysztof
    Kozoowska, Agata
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (06) : 1346 - 1351
  • [27] Children's involvement in the rabies post-exposure prophylaxis: a qualitative study in Bajawa, Indonesia.
    Marpaung, Y. M.
    Wentink, C.
    Theresia
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 112 - 112
  • [28] Epidemiological Study of Outpatients in Rabies Post-Exposure Prophylaxis Clinics - Tianjin Municipality, China, 2020
    Liu, Yifang
    Li, Lin
    Lyu, Jie
    Su, Cheng
    CHINA CDC WEEKLY, 2021, 3 (39): : 822 - 824
  • [29] Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV)
    Fayaz, Ahmad
    Simani, Susan
    Janani, Alireza
    Farahtaj, Firouzeh
    Biglari, Peyvand
    Howeizi, Nader
    Eslami, Nasser
    VACCINE, 2011, 29 (21) : 3742 - 3745
  • [30] Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models
    Zhai, Li-li
    Wang, Hui
    Zhao, Wei
    Zhang, Shou-feng
    Miao, Fa-ming
    Cao, Yang
    Chen, Chen
    Li, Yu-Feng
    Gao, Jie
    Lv, Ruo-yun
    Zhang, Shi-xiong
    Cao, Jia-bin
    Zhang, Xu-fan
    Yang, Ming-ming
    Zhang, Bin
    Zhao, Jing
    Wei, Jing-shuang
    Gao, Jian
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2022, 46